Lorcaserin: A novel antiobesity drug

ABSTRACT

Obesity is a major co-morbidity with hypertension and diabetes mellitus. There are few drugs for treatment of obesity like orlistat and recentlty approved drug lorcaserin. Lorcaserin has serotonergic properties and acts as an anorectic. It may cause serious side effects, including serotonin syndrome, particularly when taken with certain medicines that increase serotonin levels or activate serotonin receptors. Although, mainstay and first line of approach of treatment will always remain in having low calorie diet and increase in physical activity. Lorcaserin has come as a new hope to achieve success in treating obese patients but still a long road with further extensive research to be undertaken in the treatment of obesity.

KEYWORDS

• Lorcaserin
• obesity
• serotonin

Showing references and in-text citations exactly as published.

Cite this article

• DOI10.4103/0976-500X.130158Copy

RELATED ARTICLES

Matched on section and article type within this issue of J Pharmacol. Pharmacother..

• Article · VOLUME 5, ISSUE 2Identification of risk factors for carbamazepine‑induced serious mucocutaneous adverse reactions: A case‑control study using data from spontaneous adverse drug reaction reportsIlma Bertulyte, Sofie Schwan, Pär Hallberg · pp. 100–138Same type: Article
• Article · VOLUME 5, ISSUE 2Assessment of demographics, treatment strategies, and evidence‑based medicine use among diabetic and non‑diabetic patients with acute coronary syndrome: A cohort studyBhavik S. Shah, Shrikalp S. Deshpande · pp. 139–144Same type: Article
• Article · VOLUME 5, ISSUE 2Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosisKalpesh Jain, Mira Desai, Rajesh Solanki, Ram Kumar Dikshit · pp. 145–149Same type: Article
• Article · VOLUME 5, ISSUE 2Informed Consent on CameraSmita Sontakke, Parag Kinge · pp. 150–151Same type: Article